From Marcia C. Bowling, MD, Gynecologic Oncologist with OHC

September 30, 2020

During my career as a gynecologic oncologist with OHC, my colleagues and I have seen some remarkable advancements in the treatment of ovarian cancer. This includes the introduction of robotic-assisted surgery, new FDA-approved drugs, and promising new drugs being evaluated in clinical trials.

While this is promising, the fact remains that of the estimated 21,750 women who will be diagnosed with ovarian cancer this year, 80% will be in the advanced stages where treatment options are limited and the prognosis is poor.

A contributing factor to this bleak statistic is the inability to detect the disease in an early stage. There has been a great deal of research to develop a screening test for ovarian cancer, but there hasn’t been much success so far.

Another challenge is that the signs and symptoms, if present, can be ignored or mistaken for other, less serious conditions.

So, what can women do?

They can familiarize themselves with the signs and symptoms of ovarian cancer, have routine check-ups and contact their doctor if they notice these or any other changes in their health or body. Meanwhile, at OHC, we’re committed to making new treatments and supportive programs available to women in this region.

  • Our team of gynecologic oncologists are highly experienced with the Da Vinci robotic surgery. For patients for whom this is an option, it has been shown to offer less postoperative pain, less bleeding, a shorter time in the hospital, faster overall recovery, lower risk of complications, and less scarring.
  • We’re making promising new ovarian cancer treatments available to women through our nationally recognized clinical trials program. And a number of these trials are specifically for women diagnosed with late-stage ovarian cancer.
  • We introduced our cancer genetics program to help patients identify DNA mutations and reduce their risk of ovarian cancer and their family’s risk.

We understand that without a screening test for early detection, a strong focus of ovarian cancer treatment must include options for late stage disease. Patients can turn to OHC for leading-edge treatments and promising new therapies being evaluated in clinical trials, as well as supportive care for emotional, spiritual and financial needs. To learn more about ovarian cancer, treatments and clinical trials, or to request a second opinion, visit ohcare.com or call 1-888-649-4800.

OHC’s Marcia C. Bowling, MD, FACOG, is a ground-breaking gynecologic oncologist who was considered one of the world’s most experienced gynecologic oncologists in the use of robot-assisted surgery at the time of its introduction. Dr. Bowling is still considered a leading expert in robot-assisted surgery, gynecologic malignancies and complex gynecologic cases. She is a Fellow of the American College of Obstetrics and Gynecology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *